KLOW80 | Dulaglutide Retatrutide KLOW80 TB500 GHK-CU China Fast Delivery High purity Peptide Factory 99% Jack
2 Inquiries
923950-08-7
Pharmaceutical
99%
Hong Kong
HUATAI
10vial
2026-11-08
Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceDulaglutide, a GLP-1 receptor agonist that is administered subcutaneously once weekly, has been approved since 2014 for the treatment of adults with type 2 diabetes.Basic Info
-
Product Name:
Dulaglutide
Other Name:Dulaglutide - solution in PBS;Dulaglutide USP/EP/BP;Dulaglutide;Research Grade Dulaglutide(DHE40129);Research Grade Dulaglutide;Dulaglutide (Trulicity;LY2189265);Dulaglutide(sodium salt)
CAS No.:923950-08-7
Molecular Weight:0
EC Number:200-001-8
Color/Form:Colorless to light yellow
Categories:
Research-
Class:
GLP-1 receptor agonist (GLP-1 analog fused to human IgG4-Fc, long-acting)
Status:FDA-approved (Trulicity 2014)
Mechanism:A long-acting GLP-1 receptor agonist consisting of a modified human GLP-1 molecule (7-37) covalently linked to a modified human IgG4 Fc fragment via a small peptide linker. The Fc fusion extends the half-life to ~5 days, allowing once-weekly dosing. Activates GLP-1R to enhance glucose-dependent insulin secretion, suppress glucagon, and slow gastric emptying.
Activity note:Dulaglutide is a dual-agonist with GLP-1R activation. The exact EC50 is proprietary; functional potency is comparable to other long-acting GLP-1R agonists.
Source:DrugBank: DB09095; PubChem CID 16135271.
Clinical Development:FDA:Trulicity (approved 2014-09-18)
References-
DrugBank:PubChem:Disclaimer:
Dulaglutide is FDA-approved as a prescription medicine (Trulicity) for type 2 diabetes. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide
-
Location:
1502A1, Building 4, Xinyuanxin Center, No. 3 Huaxin Road, Dongfeng Street, Licheng District, Jinan City, Shandong Province
-
Payment Terms:
TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
1
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
51-100
-
Year of Establishment:
2026
-
Certifications:
COA,COA,COA,COA,COA,COA,COA,COA,COA,COA,COA,COA
-
-
Inquiry History2 Inquiries
Country Product Purchase Quantity Date Posted
Turkey
Dulaglutide
1 G Jun 5, 2026
United States
dulaglutide
4 Mar 11, 2026 Post an enquiry for this product